

A/Prof Matthew Foote BSc, MBBS (Hons), FRANZCR

SPECIALIST AREAS

Associate Professor Matthew Foote has special interests in stereotactic brain and body radiotherapy, neuro-oncology, and advanced skin cancer treatment. He is currently the Co-Director of the Gamma Knife® Centre of Queensland at the Princess Alexandra Hospital and an examiner for the University of Queensland Medical School.

EDUCATION

Associate Professor Foote completed a Bachelor of Science with Commendation for High Achievement and a Bachelor of Medicine and Surgery in 2002 with Honours, receiving The Neville G. Sutton Prize in surgery & The Charles Mitford Lilley Memorial Prize for surgery. Having completed his advanced training in Radiation Oncology in 2009, he commenced a clinical and research fellowship (focused on neuro-oncology and stereotactic radiotherapy) at the Princess Margaret Hospital, Toronto, Canada.

He then returned to Australia in 2010 to take up a staff specialist position at the Princess Alexandra Hospital Radiation Oncology Centre where he was instrumental in establishing the Gamma Knife® Centre of Queensland (the first public cancer treatment facility of its kind in Australia).

RESEARCH & PUBLICATIONS

Associate Professor Foote is a principal investigator of international, national & local clinical trials in melanoma, non-melanoma skin cancer and neuro-oncology. In research he is involved with TROG, ANZMTG, COGNO and the Translational Research Institute. He is also a reviewer for national and international journals and has published papers on stereotactic spine radiotherapy highlighting his expertise and collaboration with leaders in this field.

AWARDS & MEMBERSHIPS

Associate Professor Foote represents Australasia on the Elekta Oligometastasis Consortium, a group dedicated to outcomes research using stereotactic body radiotherapy and has been elected by his peers to the International Stereotactic Radiosurgery Society (ISRS) which supports stereotactic body and brain research internationally.

He is a member of the Co-operative Trials Group for Neuro-oncology (COGNO), Australia and New Zealand Melanoma Trials Group (ANZMTG), the Australia and New Zealand Head and Neck Cancer Society (ANZHNCs), and the Trans Tasman Radiation Oncology Group (TROG).

In the community he is involved with the Queensland Cancer Council, Cure Brain Cancer Foundation and is a patron of the Queensland Acoustic Neuroma Association (QANA). Since 2011 his body of work has attracted in excess of \$8.5 million in private and government investment, receiving grants from the NHMRC and Cancer Australia.

He is committed to providing patient focused care and is at the forefront of innovative radiation therapy practice.

